Ben Ruprecht
Director, Proteomics Blueprint Medicines
Benjamin Ruprecht serves as Director of Proteomics at Blueprint Medicines, pioneering mass spectrometry-based proteomics. He has extensive proteomics experience, having worked at Merck, Roivant Therapeutics and Covant Therapeutics. He holds a PhD from the Technical University of Munich.
Seminars
Thursday 5th February 2026
Quantitative Post-Translational Modifications (PTM) Omics to Support Drug Discovery
11:45 am
- Discussing optimized experimental PTM enrichment workflows for increased sensitivity and robustness
- Benchmarking novel mass spectrometers and proteomic data processing tools for enhanced coverage of the PTM-ome
- Sharing examples for the application of PTM data to guide decision-making in different stages of the drug discovery process
